Category: Research
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
Moderna’s Cancer Vaccine Program
Highly successful Covid vaccines have raised the question of ‘why not cancer vaccines?’, a question of great interest and financial contribution for the ALK Positive NSCLC community in recent years. […]
-
WE NEED YOUR INFO: Take part in our longitudinal survey of ALK+ Cancer Patients
More participants = more data = better research = more life!We invite you to complete a patient survey/registry specific to ALK-positive lung cancer. This is an IRB approved professionally study […]
-
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
by Mizuta et al. (Japan) A common problem that we face is that cancer becomes resistant to our TKIs (Crizotinib, Brigatinib, Alectinib, Ceritinib, and Lorlatinib) over time. There are two […]
-
An Interview with Dr. Alice Shaw at ALKtALK, Feb. 2022
Dr. Alice Shaw, MD, PhD, Boston, MA Global Head of Translational Clinical Oncology at Novartis Attending physician, Center for Thoracic Cancers at Massachussets General Hospital Associate Professor of medicine at […]
-
LUNGevity Partners with ALK Positive to Award $1.5 Million in Lung Cancer Research Grants
FOR IMMEDIATE RELEASEMedia ContactColin Bartonmedical@alkpositive.org303-204-3388 WASHINGTON, DC (January 27, 2022) — LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the […]
-
$7.6M Gift Launches New Lung Cancer Research Initiative at University of Michigan’s Rogel Cancer Center
EDITOR’S NOTE: This is a reprint of a press release from the University of Michigan’s Rogel Cancer Center – this $7.6 million gift from Judith L. Tam and the Richard […]
-
Understanding ALK structural data
“Know thy self, know thy enemy. A thousand battles, a thousand victories”; a quote by the famous Chinese historical figure Sun Tzu. Accordingly, scientists have been working hard at understanding the […]
-
Sequencing treatment in ALK-positive cancer
The proverbial question, “what is my best treatment option?” is always on a patient’s mind. With the current treatment options available to us, ALKies, “what should we do?” comes up […]
-
Dr. Ou at ALKtALK
Dr. Ignatius Sai-Hong Ou – Professor in Hematology-Oncology, Medical Oncology University of California, Irvine Editor-in-Chief of Lung Cancer: Targets and Therapy Associate Editor of Journal of Thoracic Oncology Question: We […]
-
International Ambassadors Survey- ALK Life Study
An informal survey was conducted with our ALK International Ambassadors, volunteers from various countries who are passionate about sharing their experiences with others. A total of 22 countries were represented […]